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This patient was a 33 year old, gravida 5, para 4, which is a little high in our 
country.  She had noticed a brown-pigmented mole on her leg, which she had had 
for about two years.  She had shown this to some healthcare workers, but they had 
reassured her.  At 17 weeks pregnancy it was becoming quite large and ulcerated and 
she was referred to see a plastic surgeon, who undertook an excisional biopsy and 
this confirmed the diagnosis of malignant melanoma.  There are various ways of 
classifying melanoma. The Breslow classification is thought to be the most 
prognostic, particularly for deeply invading lesions as this one was, measuring 
6.2mm. This corresponds to Stage 2C, or Clarke’s level V. 
The real difficulty for us with this particular individual was that on the 
ultrasound scan there was a singleton pregnancy with a normal looking placenta and 
normal liquor, but there was a uterine mass, which had not been seen on the 11 week 
scan.  It was on the right side, it seemed to have the appearance of myometrium, it 
would possibly have passed for a rudimentary horn in a unicorunate uterus, but the 
concern clearly was that this was a metastisis from melanoma and that threw us into 
quite some difficulties deciding how to care for her. 
Now the implications of this diagnosis for the mother was that she had a very 
poor prognosis really in any case.  Furthermore, there was risk to the fetus.  
Malignant melanoma is one of the commonest tumours that causes metastasis from 
the mother to the fetus and where placenta is involved there is a 22% risk that the 
fetus will develop metastases. In the few studies that have been published on this, 
more or less all of these babies will die.  To consider how we would plan her 
management we needed to do a little bit of background thinking. 
 
The incidence of melanoma is increasing slowly in the UK and America.  It is 
thought now that there is a 1% lifetime risk.  The average age of presentation is 45 
years old.  One third of the patients are of child bearing age.  It accounts for 8% of 
malignant disease that occurs in pregnancy.  As far as this relationship to hormones 
is concerned early studies did show a large number of oestrogen, progesterone and 
androgen receptors on malignant melanoma cells.  We know that in pregnancy that 
MSH increases and pigmentation tends to increase also.  Some studies suggest 
pregnant women have worse survival.  With more modern monoclonal antibody 
analysis, in fact the receptor count on malignant melanoma cells is quite low.  There 
does not seem to be an increased incidence in women taking the combined pill and 
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treatment attempts with anti-oestrogen’s have been very disappointing.  As I said 
pregnant women possibly do slightly worse, but the results are conflicting and where 
the studies have been properly stratified or staged there is probably no difference in 
five year survival. 
We obviously has a problem here with potential metastasis and how we would 
best treat this women in order to enable her the best chance of survival.  
Chemotherapy has been used with malignant melanoma and agents that seem to offer 
some sort of effectiveness include INF and Dacarbazine.  INF has been used in 
pregnancy for conditions such as myeloma, but at much lower doses than is required 
for melanoma and there is really no certainty that it would be safe to give that.  
Dacarbazine has been used in pregnancy without significant fetal side effects, other 
than possibly a relationship with intrauterine growth retardation. 
Now the diagnosis of metastatic melanoma carries a very poor prognosis 
indeed and is very rarely curable.  However, there are reports that where there is an 
isolated metastatic site surgical resection does offer long term survival in some cases 
and you can see that to resect metastasis in the pregnant uterus would have very final 
consequences for the fetus.  Finally there are reports of spontaneous regression for 
this condition, but that is a very rare event, almost certainly less than 1%. 
So we entered into some lengthy discussions with our oncologists and we 
undertook an MRI scan of the whole of this patient from one end to the other and we 
did not identify any evidence of metastasis elsewhere.  We asked our radiologist to 
undertake a biopsy, which was ultrasound guided.  He obtained a biopsy result that 
was normal myometrium and this of course threw us into debate again because ones 
tendency when a biopsy result is normal tissue is to assume that the biopsy was 
inaccurate and to consider repeating it. However, there would be consequences of 
repeatedly putting a biopsy needle into a pregnant uterus.  The individual who 
undertook the biopsy was absolutely certain he has put it into the right place and so 
we decided that we would accept the result, that this was not, in fact, a metastasis to 
the uterus.  The other factor here was that this individual was very, very keen to 
continue with the pregnancy and really, I think, would have allowed her own health 
to deteriorate for the well being of her child.  So, the pregnancy was allowed to 
continue and the baby actually grew well, but sadly she developed an inguinal mass 




The oncologists clearly then wanted to start to give some form of 
chemotherapy, but they were happy to delay this until fetal maturity.  She in fact 
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delivered last week at 37 weeks, a normal healthy delivery of a boy and the placental 
histology is in fact negative.  So the outlook for this particularly baby is probably 
very good, but I am afraid the outlook for the mother still remains at around 25% 




This graph is to show you that the incidence of melanoma has been increasing 
in Britain and the UK.  Possibly the downturn at the end of the graph just might 
reflect public health education on use of barrier creams for protection against the sun 
in those of us who have very low pigment levels in our skin, but we have yet to see. 
 
 
